Optimist Retirement Group LLC Buys 8,195 Shares of Pfizer Inc. (NYSE:PFE)

Optimist Retirement Group LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 12.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 73,845 shares of the biopharmaceutical company’s stock after acquiring an additional 8,195 shares during the period. Pfizer makes up approximately 1.1% of Optimist Retirement Group LLC’s holdings, making the stock its 26th largest holding. Optimist Retirement Group LLC’s holdings in Pfizer were worth $2,066,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the company. Olistico Wealth LLC acquired a new position in shares of Pfizer in the second quarter valued at $25,000. MFA Wealth Advisors LLC bought a new stake in Pfizer in the 2nd quarter valued at $29,000. Creekmur Asset Management LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $32,000. Trivant Custom Portfolio Group LLC lifted its holdings in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares during the period. Finally, Financial Connections Group Inc. acquired a new stake in shares of Pfizer during the 2nd quarter valued at about $34,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of Pfizer stock opened at $29.75 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The firm has a 50 day simple moving average of $29.33 and a 200 day simple moving average of $28.19. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $34.11. The firm has a market cap of $168.58 billion, a P/E ratio of -495.75, a P/E/G ratio of 1.02 and a beta of 0.68.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period last year, the firm earned $0.67 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were issued a dividend of $0.42 per share. The ex-dividend date was Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.65%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Analysts Set New Price Targets

Several research firms recently issued reports on PFE. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Wells Fargo & Company lifted their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, UBS Group upped their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.